Efficacy and safety of transarterial chemoembolization and radiofrequency ablation plus tyrosine kinase inhibitors with or without programmed cell death protein-1 inhibitors for unresectable hepatocellular carcinoma
British Journal of Radiology · 01.08.2026 · 99 (1184) · 1569-1578
DOI: 10.1093/bjr/tqag100 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Radiology, online erschienen am 04.05.2026. Verfasst von Yue Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Radiofrequency Ablation. Die Arbeit nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objectives
The purpose of this study was to compare the efficacy and safety of transarterial chemoembolization combined with radiofrequency ablation (TACE-RFA) plus tyrosine kinase inhibitors (TKI) with or without programmed cell death protein-1 (PD-1) inhibitors in the treatment of unresectable hepatocellular carcinoma (uHCC).
Methods
From January 2020 to October 2024, 87 patients with uHCC who received TACE-RFA plus TKI with or without PD-1 inhibitors in our center were retrospectively analyzed, and divided into TACE-RFA + TKI (TRK) group and TACE-RFA + TKI + PD-1 (TRKP) group. Kaplan-Meier method and log-rank test were used to analyze overall survival (OS) and progression-free survival (PFS) of the 2 groups. Adverse events (AEs) between the 2 groups were evaluated according to Common Adverse Event Evaluation Criteria (CTCAEs) Version 5.0.
Results
The patients in the TRKP group had longer median OS (mOS) (24 [95% confidence interval (CI): 17.7-30.3] vs. 18 [95% CI: 15.1-20.9] months, P = .04) and median PFS (mPFS) (15[95% CI: 13.4-16.6] vs. 12 [95% CI: 10.8-13.2] months, P = .01) than that in the TRK group. The objective response rate (ORR) (44.19% vs 36.36%, P = .03) and disease control rate (DCR) (86.05% vs. 70.45%, P = .08) in the TRKP group were better than those in the TRK group. There was no significant difference in the frequency and severity of AEs between the 2 groups.
Conclusions
The treatment of TACE-RFA + TKI + PD-1 inhibitors is effective and safe for uHCC. Advances in knowledge This study advances knowledge by showing that the TACE-RFA + TKI + PD-1 (TRKP) regimen is more effective than TACE-RFA + TKI (TRK) in improving median overall survival, median progression-free survival, and objective response rate for unresectable hepatocellular carcinoma (uHCC) with controllable adverse events, and identifies TRKP as an independent favorable prognostic factor, while AFP ≥400 ng/mL and BCLC stage C as adverse prognostic factors for uHCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
- Department of General Surgery, Youan Hospital, Capital Medical University, Beijing 100054, China.
ORCID-Profile: Tao Luo
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, Y., Jia, L., Sun, Y., Wang, Z., Li, Y., Wang, J., Zhang, C., Bian, C., Lin, D., & Luo, T. (2026). Efficacy and safety of transarterial chemoembolization and radiofrequency ablation plus tyrosine kinase inhibitors with or without programmed cell death protein-1 inhibitors for unresectable hepatocellular carcinoma. British Journal of Radiology, 99(1184), 1569-1578. https://doi.org/10.1093/bjr/tqag100
Vancouver
Chen Y, Jia L, Sun Y, Wang Z, Li Y, Wang J, et al. Efficacy and safety of transarterial chemoembolization and radiofrequency ablation plus tyrosine kinase inhibitors with or without programmed cell death protein-1 inhibitors for unresectable hepatocellular carcinoma. British Journal of Radiology. 2026;99(1184):1569-1578. doi:10.1093/bjr/tqag100
BibTeX
@article{Chen2026,
author = {Chen, Yue and Jia, Luyao and Sun, Yibo and Wang, Zhenshun and Li, Yu and Wang, Jukun and Zhang, Chao and Bian, Chunjing and Lin, Dongdong and Luo, Tao},
title = {Efficacy and safety of transarterial chemoembolization and radiofrequency ablation plus tyrosine kinase inhibitors with or without programmed cell death protein-1 inhibitors for unresectable hepatocellular carcinoma},
journal = {British Journal of Radiology},
year = {2026},
volume = {99},
number = {1184},
pages = {1569--1578},
doi = {10.1093/bjr/tqag100}
}
EUVIMED